Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has launched Clarithromycin extended-release tablets, USP in the 500mg strength.
Subscribe to our email newsletter
Watson’s Clarithromycin extended-release product is the generic equivalent to Abbott’s Biaxin XL, which is indicated to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
The FDA granted final approval of Watson’s abbreviated new drug application (ANDA) for Clarithromycin extended-release on June 24, 2004. Patent infringement litigation related to Watson’s ANDA was dismissed with prejudice on July 12, 2007.